Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting

Basit Öğe Kaydı
dc.authorid0000-0001-9081-2405
dc.authorid0000-0001-9081-2405
dc.authorscopusid6701472672
dc.authorscopusid24345297000
dc.authorscopusid8666331800
dc.authorwosidseber, selcuk e/H-3327-2017
dc.authorwosidseber, selcuk/T-9539-2019
dc.contributor.authorŞeber, Erdoğan Selçuk
dc.contributor.authorSolmaz, Dilek
dc.contributor.authorYetişyiğit, Tarkan
dc.date.accessioned2022-05-11T14:12:46Z
dc.date.available2022-05-11T14:12:46Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: Antihormonal treatment is an effective therapy in the adjuvant setting. However, musculoskeletal pain is a common adverse effect encountered in patients receiving this treatment. We aimed to evaluate the risk factors for the development of antihormonal treatment-associated musculoskeletal pain (AHAMP) and its impact on the health-related quality of life (HRQOL). Patients and methods: A cross-sectional survey of 78 consecutive breast cancer patients receiving adjuvant antihormonal treatment for early-stage breast cancer in an academic medical oncology clinic was conducted. AHAMP was assessed by Health Assessment Questionnaire (HAQ) and 10 cm visual analog scale (VAS). HRQOL was assessed by self-administered short form 36 and Functional Assessment of Cancer Therapy-Breast subscale surveys. Results: AHAMP was found to be present in 37 (47.7%) patients. In multivariate regression analysis, having a normal body mass index (<30 kg/m(2)), cigarette smoking, and low serum vitamin D level (20 ng/mL) were found to be independent risk factors. In HRQOL assessment, physical and mental scores were found to be significantly lower in patients with joint arthralgia. Conclusion: AHAMP has an adverse effect on the quality of life of breast cancer patients receiving adjuvant antihormonal treatment, and assessment of predictive factors is important for identification of patient groups at risk of developing this condition.
dc.identifier.doi10.2147/OTT.S108968
dc.identifier.endpage4935
dc.identifier.issn1178-6930
dc.identifier.pmid27563249
dc.identifier.scopus2-s2.0-84988904908
dc.identifier.scopusqualityQ2
dc.identifier.startpage4929
dc.identifier.urihttps://doi.org/10.2147/OTT.S108968
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5666
dc.identifier.volume9
dc.identifier.wosWOS:000381056300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorŞeber, Erdoğan Selçuk
dc.institutionauthorSolmaz, Dilek
dc.institutionauthorYetişyiğit, Tarkan
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofOncotargets and Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectantineoplastic hormonal agents
dc.subjectmusculoskeletal pain
dc.subjectbreast cancer
dc.subjectQuality-Of-Life
dc.subjectAromatase Inhibitor Therapy
dc.subjectBone-Mineral Density
dc.subjectPremenopausal Women
dc.subjectEstrogen Deprivation
dc.subjectPostmenopausal Women
dc.subjectEndocrine Therapy
dc.subjectJoint Symptoms
dc.subjectRisk-Factors
dc.subjectTamoxifen
dc.titleAntihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5666.pdf
Boyut:
517.74 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu